首页> 外文会议>IEEE International Conference on Bioinformatics and Biomedicine >Computational Analysis of Structural Dynamics of EGFR and its Mutants
【24h】

Computational Analysis of Structural Dynamics of EGFR and its Mutants

机译:表皮生长因子受体及其突变体的结构动力学计算分析

获取原文

摘要

Non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) is a major cause of death worldwide. Tyrosine kinase inhibitors (TKIs) have been developed to target the EGFR, stop the downstream signaling and the tumor growth. Despite of initial good results, drug resistance is developed after one year due to a secondary mutation. The L858R, T790M mutation and their combination change the conformational redistribution of EGFR. To combat drug resistance caused by the T790M mutation, AZD9291 third generation drug was approved by the food and drug administration agency, FDA, USA. However, resistance to AZD9291 is developed due to C797S mutation. In this paper, we investigate the drug resistance due to these genomic variations. We perform molecular dynamics (MD) simulation for EGFR, EGFR with L858R single point mutation, EGFR with L858R and T790M double point mutation and EGFR with L858R, T790M and C797S triple point mutation. We apply principal component analysis PCA and clustering to the atomic trajectories of EGFR and its mutants and extract the dominant motions. The first PC captures 29.04%, 51.17% 53.79% and 51.67% variance in WT, L858R, T790M and C797S mutants, respectively. First 20 PCs are used to explain the dynamics of the system, that captures about 90% of the variance in the system. This shows that the mutation increases the variance which leads to structural and dynamical changes and can be one of the reasons for the drug resistance. Our results provide new insights to the conformational dynamics and structural changes in EGFR and its mutants, that can be helpful for understanding the drug resistance mechanism and designing future therapies for NSCLC patients.
机译:具有活化表皮生长因子受体(EGFR)的非小细胞肺癌(NSCLC)是全球范围内的主要死亡原因。酪氨酸激酶抑制剂(TKIs)已被开发来靶向EGFR,阻止下游信号传导和肿瘤生长。尽管最初取得了良好的结果,但由于二次突变,一年后仍产生了耐药性。 L858R,T790M突变及其组合改变了EGFR的构象重新分布。为了对抗由T790M突变引起的耐药性,美国食品和药物管理局(FDA)批准了AZD9291第三代药物。但是,由于C797S突变,对AZD9291产生了抗药性。在本文中,我们研究了由于这些基因组变异而引起的耐药性。我们对EGFR,具有L858R单点突变的EGFR,具有L858R和T790M双点突变的EGFR和具有L858R,T790M和C797S三点突变的EGFR进行分子动力学(MD)模拟。我们将主成分分析PCA和聚类应用于EGFR及其突变体的原子轨迹,并提取主要运动。第一台PC分别捕获了WT,L858R,T790M和C797S突变体中的29.04%,51.17%,53.79%和51.67%的变异。首先使用20台PC来解释系统的动态,它捕获了系统中大约90%的差异。这表明突变增加了变异,导致结构和动力学变化,并且可能是耐药性的原因之一。我们的结果为EGFR及其突变体的构象动力学和结构变化提供了新的见解,有助于理解耐药机制并为NSCLC患者设计未来的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号